X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Janssen will develop, manufacture, and commercialize CAR T-based cell therapy candidates with Simcha’s novel proprietary decoy-resistant IL-18 (DR-18) for a set number of programs.
Lead Product(s): CAR T-based Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: JANSSEN BIOTECH
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 08, 2024
Details:
The collaboration aims to evaluate clinical safety and benefits of ST-067, Simcha’s decoy resistant IL-18 agent, in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with solid tumors.
Lead Product(s): ST-067,Pembrolizumab
Therapeutic Area: Oncology Product Name: ST-067
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 05, 2023
Details:
In addition, the Company has dosed the first patient in the Phase 1 portion of a first-in human multi-center Phase 1/2 clinical trial of its first drug candidate ST-067, a first-in-class “decoy-resistant” Interleukin-18 variant.
Lead Product(s): ST-067
Therapeutic Area: Oncology Product Name: ST-067
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BVF Partners
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 27, 2022
Details:
Simcha’s lead program involves a customized variant of interleukin-18 (IL-18), a cytokine with potent antitumor effects, developed in the lab of Scientific Founder Aaron Ring, M.D., Ph.D., Assistant Professor of Immunobiology at the Yale School of Medicine.
Lead Product(s): ST-067
Therapeutic Area: Oncology Product Name: ST-067
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: WuXi AppTec Inc.
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 24, 2020
Details:
Oral presentation and poster detail DR-18’s ability to re-animate exhausted NK cells, bias differentiation of T cells toward highly active effectors and expand the population of critical immune cells inside the tumor microenvironment.
Lead Product(s): DR-18
Therapeutic Area: Oncology Product Name: DR-18
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
